Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1093403/full |
| _version_ | 1828115852255297536 |
|---|---|
| author | Hao Zheng Hao Zheng Hao Zheng Hao Zheng Hao Zheng Wen-juan Zheng Zhen-guang Wang Zhen-guang Wang Zhen-guang Wang Yuan-ping Tao Zhi-ping Huang Le Yang Liu Ouyang Zhi-qing Duan Yi-nuo Zhang Bo-ning Chen Dai-min Xiang Gang Jin Lu Fang Fan Zhou Bo Liang |
| author_facet | Hao Zheng Hao Zheng Hao Zheng Hao Zheng Hao Zheng Wen-juan Zheng Zhen-guang Wang Zhen-guang Wang Zhen-guang Wang Yuan-ping Tao Zhi-ping Huang Le Yang Liu Ouyang Zhi-qing Duan Yi-nuo Zhang Bo-ning Chen Dai-min Xiang Gang Jin Lu Fang Fan Zhou Bo Liang |
| author_sort | Hao Zheng |
| collection | DOAJ |
| first_indexed | 2024-04-11T12:47:01Z |
| format | Article |
| id | doaj.art-01ed9e027c194d7e9bd66208810f0b48 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T12:47:01Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-01ed9e027c194d7e9bd66208810f0b482022-12-22T04:23:18ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-12-011310.3389/fimmu.2022.10934031093403Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activityHao Zheng0Hao Zheng1Hao Zheng2Hao Zheng3Hao Zheng4Wen-juan Zheng5Zhen-guang Wang6Zhen-guang Wang7Zhen-guang Wang8Yuan-ping Tao9Zhi-ping Huang10Le Yang11Liu Ouyang12Zhi-qing Duan13Yi-nuo Zhang14Bo-ning Chen15Dai-min Xiang16Gang Jin17Lu Fang18Fan Zhou19Bo Liang20Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Reproductive Heredity Center, Changhai Hospital, Second Military Medical University, Shanghai, ChinaThird Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, ChinaKey Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai, ChinaShanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai, ChinaDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaThird Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, ChinaKey Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai, ChinaShanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai, ChinaNational Liver Tissue Bank, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, ChinaDepartment of Hepatobiliary Surgery, General Hospital of Southern Theatre Command, Guangzhou, ChinaNational Liver Tissue Bank, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, ChinaDepartment of Hepatobiliary Pancreatic Surgery, Changhai Hospital of Second Military Medical University, Shanghai, ChinaDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Hepatobiliary Pancreatic Surgery, Changhai Hospital of Second Military Medical University, Shanghai, ChinaDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Chinahttps://www.frontiersin.org/articles/10.3389/fimmu.2022.1093403/fullN6-methyladenosineMETTL14Siah2PD-L1immunotherapy |
| spellingShingle | Hao Zheng Hao Zheng Hao Zheng Hao Zheng Hao Zheng Wen-juan Zheng Zhen-guang Wang Zhen-guang Wang Zhen-guang Wang Yuan-ping Tao Zhi-ping Huang Le Yang Liu Ouyang Zhi-qing Duan Yi-nuo Zhang Bo-ning Chen Dai-min Xiang Gang Jin Lu Fang Fan Zhou Bo Liang Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity Frontiers in Immunology N6-methyladenosine METTL14 Siah2 PD-L1 immunotherapy |
| title | Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity |
| title_full | Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity |
| title_fullStr | Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity |
| title_full_unstemmed | Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity |
| title_short | Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity |
| title_sort | corrigendum decreased expression of programmed death ligand l1 by seven in absentia homolog 2 in cholangiocarcinoma enhances t cell mediated antitumor activity |
| topic | N6-methyladenosine METTL14 Siah2 PD-L1 immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1093403/full |
| work_keys_str_mv | AT haozheng corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT haozheng corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT haozheng corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT haozheng corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT haozheng corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT wenjuanzheng corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT zhenguangwang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT zhenguangwang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT zhenguangwang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT yuanpingtao corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT zhipinghuang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT leyang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT liuouyang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT zhiqingduan corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT yinuozhang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT boningchen corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT daiminxiang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT gangjin corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT lufang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT fanzhou corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity AT boliang corrigendumdecreasedexpressionofprogrammeddeathligandl1byseveninabsentiahomolog2incholangiocarcinomaenhancestcellmediatedantitumoractivity |